Association between polymyalgia rheumatica and vascular disease: A systematic review
Article first published online: 27 AUG 2012
Copyright © 2012 by the American College of Rheumatology
Arthritis Care & Research
Volume 64, Issue 9, pages 1301–1305, September 2012
How to Cite
Hancock, A. T., Mallen, C. D., Belcher, J. and Hider, S. L. (2012), Association between polymyalgia rheumatica and vascular disease: A systematic review. Arthritis Care Res, 64: 1301–1305. doi: 10.1002/acr.21712
- Issue published online: 27 AUG 2012
- Article first published online: 27 AUG 2012
- Accepted manuscript online: 18 APR 2012 09:40AM EST
- Manuscript Accepted: 12 APR 2012
- Manuscript Received: 7 NOV 2011
- Jean Shanks foundation intercalated degree grant
- Arthritis Research UK clinician scientist grant
To systematically identify and appraise the existing literature on the association between polymyalgia rheumatica (PMR) and vascular disease.
The Medline, Embase, CINAHL, and Cochrane databases were searched from inception to September 2010. Search criteria included observational studies containing patients with isolated PMR reporting on a vascular outcome. Data were extracted and articles were assessed for quality.
The database search identified 545 articles. Eight articles reporting on 7 unique studies were included in the final review. Four studies reported on vascular mortality and 3 studies reported on other vascular outcomes. Four of the studies reported statistically significant positive associations between PMR and vascular disease and 3 studies reported no statistically significant results. The heterogeneity of the results was investigated; the strongest explanatory variable was that 2 of 3 studies that reported nonsignificant results were prospective, whereas all of those studies reporting significant results were retrospective.
There is some evidence to suggest that, like other inflammatory rheumatic disorders, PMR may be linked to an increased risk of vascular disease. Further studies are required to quantify the level of risk to determine whether patients with PMR should be actively screened for cardiovascular disease and its risk factors.